Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Query: "TILT[LastUpdatePostDate]SEARCH[Study]AREA[SponsorSearch]Cancer Advances Inc."
Count: 15
Selected: 0
NCT IDTitle
NCT03200821An Open Label Study to Evaluate G17DT Compared to Gemcitabine
NCT02223078Two Center Study to Determine Effect of G17DT on Plasma Gastrin Levels in Patients With Colorectal Cancer.
NCT02521649Dose-ranging Study to Evaluate Antibody Response to G17DT in Patients With Gastric Cancer
NCT02518529Study to Assess Tolerability and Safety and Antibody Response to G17DT in Gastric Cancer Patients
NCT02518373Effect of G17DT in Patients With Stage II/III Colorectal Cancer
NCT02450032Study to Determine the Antibody Response to 500µg G17DT in Treatment of Patients With Gastric Cancer
NCT02233712Open-label, Dose-finding Study to Determine Antibody Response to G17DT Treatment in Patients With Gastric Cancer.
NCT02228785A Study of the Safety and Tolerance of Three Doses of G17DT in Metastatic Colorectal Cancer
NCT00042510Safety and Efficacy of G17DT Immunogen in the Treatment of Gastric and Gastroesophageal Cancer
NCT02181465Study to Assess Safety and Tolerability of G17DT in Patients With Colorectal Adenocarcinoma.
NCT02118077Sequential Trial of G17DT for the Treatment of Advanced Pancreatic Cancer
NCT02118064Phase II Study to Evaluate G17DT in Combination With Irinotecan in Patients With Colorectal Carcinoma
NCT00044031Safety and Efficacy of G17DT Immunogen Combined With Gemcitabine vs. Gemcitabine in the Treatment of Advanced Pancreatic Carcinoma
NCT02098291An Open, Single-center Study to Determine the Antibody Repsonse to Gastrimmune and Its Safety and Tolerability in Patients With Advanced Pancreatic Carcinoma
NCT02098239Single Centre Study to Determine the Antibody Response to G17DT in Patients With Advanced Pancreatic Cancer.